Axona targets diminished cerebral glucose metabolism to help nutritionally support cognition*¹

Adding Axona to Alzheimer’s disease management may address a specific nutritional deficiency not addressed by FDA-approved Alzheimer's treatments¹

Unlike the FDA-approved drug classes called acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartic acid (NMDA) receptor antagonists, Axona provides medium-chain triglycerides to the body that can be metabolized into ketone bodies as an alternative fuel source for the brain.^1,2

Diminished cerebral glucose metabolism (DCGM, also known as glucose hypometabolism) occurs early in the disease and correlates with symptoms and disease progression.^3-7 During times of DCGM, the brain can use alternative fuel sources, such as ketone bodies, to produce cellular energy.^2,8

Diminished cerebral glucose metabolism in Alzheimer’s disease^9,10

Find out more about one of the earliest brain changes that occurs in Alzheimer’s disease.

Adding Axona to Alzheimer’s disease management may address a specific nutritional deficiency not addressed by FDA-approved Alzheimer's treatments1

Diminished cerebral glucose metabolism in Alzheimer’s disease9,10

Diminished cerebral glucose metabolism in Alzheimer’s disease

Diminished cerebral glucose metabolism in Alzheimer’s disease

Prescribing Axona

Adding Axona to Alzheimer’s disease management may address a specific nutritional deficiency not addressed by FDA-approved Alzheimer's treatments¹

Diminished cerebral glucose metabolism in Alzheimer’s disease^9,10